Cita APA

Stringer, M., Abeysekera, I., Thomas, J., LaCombe, J., Stancombe, K., Stewart, R. J., . . . Roper, R. J. (2017). Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. Physiol Behav.

Chicago Style Citation

Stringer, Megan, et al. "Epigallocatechin-3-gallate (EGCG) Consumption in the Ts65Dn Model of Down Syndrome Fails to Improve Behavioral Deficits and Is Detrimental to Skeletal Phenotypes." Physiol Behav 2017.

Cita MLA

Stringer, Megan, et al. "Epigallocatechin-3-gallate (EGCG) Consumption in the Ts65Dn Model of Down Syndrome Fails to Improve Behavioral Deficits and Is Detrimental to Skeletal Phenotypes." Physiol Behav 2017.